Vanucizumab

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Advanced/Metastatic Solid TumorsColorectal CancerNeoplasms

Phase 1

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

CompletedNCT01688206

Hoffmann-La RocheNeoplasms

Start: 2012-10-31End: 2018-03-12Updated: 2018-10-05

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

CompletedNCT02665416

Hoffmann-La RocheAdvanced/Metastatic Solid Tumors

Start: 2016-01-25End: 2019-10-30Updated: 2020-04-07

Phase 2

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

TerminatedNCT02141295

Hoffmann-La RocheColorectal Cancer

Start: 2014-06-30End: 2017-02-01Updated: 2020-03-25

Related Papers

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial

Frontiers in Oncology2023-05-038 citations

Abstract 1643: Leveraging tumor size and time to death from bevacizumab (BEV) historical data to predict overall survival in ovarian cancer patients treated with vanucizumab (VAN)

Cancer Research2018-07-012 citations

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Journal of Clinical Oncology2017-05-2015 citations

Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab.

Journal of Clinical Oncology2016-05-201 citations

Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.

Journal of Clinical Oncology2015-05-207 citations

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-2014 citations